Overseas Manufacturer Market Entry Paths in Australia

1. Key takeaways

The Therapeutic Goods Act 1989 does not expressly prohibit an overseas entity from acting as a sponsor — the statutory test is who imports, or arranges the import of, the device. TGA’s official position, however, requires the sponsor to be a recognised legal entity within Australia. An overseas manufacturer therefore has three practical routes: establish its own Australian entity, appoint a third-party sponsor, or operate a hybrid model.

• The statute defines sponsorship by conduct, not by nationality.
• TGA administrative practice narrows eligibility to Australian legal entities.
• The three holding models differ in control, cost and concentration of responsibility.
• The sponsor is an element of the kind of device, so a sponsor change triggers entry variation under section 10F.

The practical consequence is that the statute and the administrative guidance must be read together. A company that plans only against the statutory definition will discover at the application stage that TGA’s account and entity verification processes require an Australian presence, and the delay of a late entity decision ripples through every downstream step, from technical documentation sign-off to label approval and first shipment.

2. Legal basis

The framework below sets out what the statute says, what TGA requires in practice, and where the practical estimate lies between the two.

1. Therapeutic Goods Act 1989 (Act No. 21, 1990): the sponsor definition appears in section 3(1); the exclusion clause states that the definition does not include a person acting on behalf of another person who resides in Australia or carries on business in Australia (that is, paragraphs 3(1)(d)(e)).
2. It follows that where an overseas manufacturer imports, or arranges the import of, a device on behalf of an Australian party, the manufacturer is not the sponsor; the sponsor is the Australian principal.
3. TGA official requirement: the sponsor must be a recognised legal entity within Australia (TGA, Medical device inclusion process, 23 November 2023). Another TGA page states that the sponsor must be an Australian resident, or a body corporate that carries on business in Australia and has a representative resident in Australia.
4. Split responsibility provisions: failure by the manufacturer to apply the relevant conformity assessment procedures is addressed in section 41ME; failure by the sponsor in section 41MF.
5. Sponsor change mechanism: Therapeutic Goods Regulations 1990, section 10F (change of sponsor) and section 10FA (change of device name).
6. [practical estimate] No quantitative official statement was found on the “statutory conditions for an overseas manufacturer to act directly as sponsor”; in practice the entity must first become an Australian legal entity.

3. Expert insights

Insight 1: the law left a gap, and administrative practice has narrowed it. The statute defines the sponsor by a conduct standard — who imports the device — and places no restriction on nationality. TGA applies an administrative standard requiring an Australian entity. Planning must follow the administrative standard; otherwise the application stalls at the account and entity verification stage. The gap is not a drafting accident. Parliament left the definition conduct-based so that liability follows the person who actually moves the goods, while the regulator keeps entry criteria narrow enough to guarantee that every sponsor can be inspected, contacted and enforced against on Australian soil.

Insight 2: the three models differ in control and concentration of responsibility. Establishing an own entity gives the strongest control but the highest set-up and operating cost; a third-party sponsor is the cheapest option but shifts the concentration of responsibility to that third party; the hybrid model, in which an own entity holds some high-risk entries while a third party holds the rest, is common in practice but requires clear tiering rules for which entries sit where. Whichever model is chosen, the agreement should record not only who pays which fee but who performs which duty, because the register only ever shows one sponsor and cannot reflect internal cost-sharing.

Insight 3: model choice feeds back into future change costs. The sponsor is one of the constituent elements of the kind of device (section 41BE(1)). Replacing the sponsor is therefore an entry variation processed under section 10F. Model selection is not a one-off decision; it determines the cost of every future adjustment. A model that looks cheap at first inclusion can become expensive the moment the portfolio grows, because every added product inherits the structural choice made at the beginning.

A final observation concerns sequencing. The entity decision sits at the top of the dependency chain: the sponsor agreement, the conformity assessment declarations, the ARTG account and the label sponsor details all reference the same legal entity, so reversing that choice later means touching every one of those documents at once. Deciding the model early, even at the cost of a slower start, is almost always cheaper than migrating between models under time pressure.

4. Practical recommendations

• Select the model against product risk and the business plan: for high-risk products or long-term commitment choose an own entity; for market testing or single products choose a third-party sponsor; for multi-category portfolios use a hybrid model with explicit tiering rules.
• State the responsibilities under section 41ME and section 41MF separately in the agreement to avoid a responsibility vacuum.
• Prepare a sponsor change plan covering trigger conditions, the section 10F process and time limits (see article 34).
• Review once a year whether the model still matches the scale of the business, especially when product numbers cross a threshold.

5. Verification checklist

• □ The requirement that the sponsor be an Australian legal entity has been confirmed against administrative practice
• □ No section 3(1) exclusion situation has been confirmed to exist
• □ The holding model has been selected against risk and business scale
• □ The agreement separates responsibilities under sections 41ME and 41MF
• □ A sponsor change plan is in place

Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team coordinates Australian sponsor arrangements, ARTG annual charges, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com